Cover Image

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Show other versions (1)

Until today, adult and pediatric clinical trials investigating single-agent or combinatorial HDAC inhibitors including vorinostat in solid tumors have largely failed to demonstrate efficacy. These results may in part be explained by data from preclinical models showing significant activity only at h...

Full description

Saved in:
Bibliographic Details
Main Authors: Tilburg, Cornelis M. van (Author) , Milde, Till (Author) , Witt, Ruth (Author) , Ecker, Jonas (Author) , Hielscher, Thomas (Author) , Seitz, Angelika (Author) , Schenk, Jens-Peter (Author) , Buhl, Juliane (Author) , Riehl, Dennis (Author) , Frühwald, Michael (Author) , Pekrun, Arnulf (Author) , Rössig, Claudia (Author) , Wieland, Regina Paula Franziska (Author) , Flotho, Christian (Author) , Kordes, Uwe (Author) , Gruhn, Bernd (Author) , Simon, Thorsten (Author) , Linderkamp, Christin (Author) , Sahm, Felix (Author) , Taylor, Lenka A. (Author) , Freitag, Angelika (Author) , Burhenne, Jürgen (Author) , Foerster, Kathrin (Author) , Meid, Andreas (Author) , Pfister, Stefan (Author) , Karapanagiotou-Schenkel, Irini (Author) , Witt, Olaf (Author)
Format: Article (Journal)
Language:English
Published: 10 December 2019
In: Clinical epigenetics
Year: 2019, Volume: 11
ISSN:1868-7083
DOI:10.1186/s13148-019-0775-1
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s13148-019-0775-1
Get full text
Author Notes:Cornelis M. van Tilburg, Till Milde, Ruth Witt, Jonas Ecker, Thomas Hielscher, Angelika Seitz, Jens-Peter Schenk, Juliane L. Buhl, Dennis Riehl, Michael C. Frühwald, Arnulf Pekrun, Claudia Rossig, Regina Wieland, Christian Flotho, Uwe Kordes, Bernd Gruhn, Thorsten Simon, Christin Linderkamp, Felix Sahm, Lenka Taylor, Angelika Freitag, Jürgen Burhenne, Kathrin I. Foerster, Andreas D. Meid, Stefan M. Pfister, Irini Karapanagiotou-Schenkel, and Olaf Witt
Description
Summary:Until today, adult and pediatric clinical trials investigating single-agent or combinatorial HDAC inhibitors including vorinostat in solid tumors have largely failed to demonstrate efficacy. These results may in part be explained by data from preclinical models showing significant activity only at higher concentrations compared to those achieved with current dosing regimens. In the current pediatric trial, we applied an intra-patient dose escalation design.
Item Description:Gesehen am 20.05.2020
Physical Description:Online Resource
ISSN:1868-7083
DOI:10.1186/s13148-019-0775-1

Similar Items